Table 2.

Pharmacological Treatment of Patients With Schizophrenia During the 180-d Period Before Starting FD, HD, or LAR

Treatment	FD Patients, % (N = 948)	HD Patients, % (N = 1631)	LAR Patients, % (N = 116)	Statistics			Group Differencesa
				χ2	df	P
Any oral antipsychotic	92.9	91.1	96.6	6.1	2	.046	LAR > HD
Any oral atypical antipsychotic	84.6	85.5	95.7	10.4	2	.006	LAR > HD, FD
Selected oral antipsychotics
Fluphenazine	34.5	3.7	9.5	45.5	2	>.0001	FD > LAR > HD
Haloperidol	13.8	42.2	23.3	227.9	2	>.0001	HD > LAR > FD
Risperidone	32.8	38.9	70.7	63.8	2	>.0001	LAR > FD, HD
Aripiprazole	3.8	4.6	16.4	36.0	2	>.0001	LAR > FD, HD
Clozapine	10.4	10.6	10.3	0.1	2	.98
Olanzapine	45.2	41.8	36.1	4.9	2	.09
Quetiapine	32.2	31.7	32.8	0.1	2	.94
Ziprasidone	13.1	11.1	14.7	3.1	2	.22
2+ Oral antipsychotics	65.1	64.0	75.0	5.5	2	.07
Antipsychotic, MPRb <0.80	53.5	58.5	61.2	6.9	2	.03	HD > FD
Antipsychotic gap >30 d	22.7	24.5	29.5	2.8	2	.24
Other psychotropic medications
Antidepressant	50.2	47.7	56.0	3.9	2	.14
Anxiolytic/hypnotic	47.2	45.4	56.9	6.1	2	.048	LAR > FD, HD
Mood stabilizer	56.3	56.1	60.3	0.8	2	.67
				F	df	P
Antipsychotic MPR, mean (SD)	0.64 (0.32)	0.61 (0.32)	0.63 (0.29)	1.6	2, 2612	.19

Note: Data from 2001 to 2004 Medi-Cal. FD denotes fluphenazine decanoate, HD denotes haloperidol decanoate, and LAR denotes long-acting risperidone. All analyses are based on 180-d period before the start of first depot injection.

^aGroup differences, P < .05.

^bMPR denotes medication possession ratio and is defined as the proportion of days of medication over the 180-d treatment period.